chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report was received from a healthcare worker refers to a 2 year old male patient. On 19-MAY-2015, the patient was vaccinated inadvertently with PROQUAD (Merck) (L004005, expiry date 05-AUG-2016) who was supposed to receive MMR II. On 07-APR-2014, the patient received VARIVAX (Merck). No adverse effects were reported. Additional information has been requested.
At 9:00 PM on the day of vaccination (8 hours after vaccination) I felt achy and tired and needed to lay down. I also had chills and soreness & swelling at the injection site. I went to bed at 10:30pm. At 1:45 AM (13 hours after vaccination) I woke up with low grade fever, chills, muscle/body aches, fatigue, headache, earache, and sore throat. I could not go back to sleep all night and by 3:00 AM (14 hours after vaccination) I also had nausea and light, dry cough. I had sharp headache and earache pangs. These symptoms persisted. At 11:00 AM the following day (22 hours after vaccination) I took Nyquil containing acetominophen. At around 4:00 AM the next night (39 hours after vaccination) my fever was gone and the other symptoms started to slowly get better the following day.
T-dap on 6/28.following day severe muscle aches, chills, achey joints,fatigue,temp,head ache,nausous.  arm site swollen, hard, hot tender,cant elevate. 3 days down w/continued symptoms.
Body Aches - Had body aches for 4 days following my 2nd dose of this vaccine.
Approximately 3 days after vaccine child developed red warm rash on left arm that was between her left elbow and shoulder only. Is painful. Rash is still present.
Chills, shivering, migraine , body aches, painful tinnitus, fever, elevated resting HR of 90 (normal is 46), bounding heart beat, tightness in chest, elevated resting BP 150/80 (normal 124/72)  600mg ibuprofen & 500mg acetametaphine made me comfortable to get about an hour and half worth of sleep.  Went to ED for elevated HR, BP and chest pain.  ED took EKG and monitored vitals.  ED discharged with 975mg acetametaphine and 800mg ibuprofen with 24hrs quarters.  I was able to get about 3 hours of sleep.
Information has been received from Company representative who was told by a friend of the patient's family. The patient was a 24 year old female patient who was vaccinated in approximately November-2008 with the third dose of GARDASIL. Concomitant therapy included influenza virus vaccine (unspecified). In approximately November-2008, the patient reported tingling in her fingers and toes shortly after the vaccinations. It got worse over night and she went to the Hospital the next day. The hospital did test for persistent numbness and the patient was sent home. The patient's mother found her crawling on the floor a few days later and she was taken by ambulance to the hospital where she was admitted, intubated and in coma. The patient was diagnosed with Guillain-Barre. As of 16-DEC-2008, the patient was still in coma. Guillain-Barre syndrome and coma were considered to be immediately life-threatening and disabling and other important medical event. No further information is available.
After 10 minutes of receiving both vaccines, patient develops urticaria (reddish and pale papules of 2-5 mm size, welts) rash in the face area, non tender, non vesicular, no fluctuation, no discharge.  After 20 minutes of a Dose a Bendryl, patient starts improving and requests to be discharged home.
Vertigo; Dizziness; Slight Frog; This spontaneous case was reported by a consumer and describes the occurrence of VERTIGO (Vertigo), DIZZINESS (Dizziness) and FEELING ABNORMAL (Slight Frog) in a 63-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 008B21A and 024M20A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included ATORVASTATIN, LISINOPRIL, MULTIVITAMINS [VITAMINS NOS], VITAMIN C [ASCORBIC ACID], IBUPROFEN and ACETYLSALICYLIC ACID (BABY ASPIRIN) for an unknown indication.   On 27-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 27-Mar-2021, the patient experienced FEELING ABNORMAL (Slight Frog). On 28-Mar-2021, the patient experienced DIZZINESS (Dizziness). On 29-Mar-2021, the patient experienced VERTIGO (Vertigo). At the time of the report, VERTIGO (Vertigo), DIZZINESS (Dizziness) and FEELING ABNORMAL (Slight Frog) outcome was unknown.            Other concomitant medications included cholesterol and blood pressure medications. Treatment information was not reported.
Arm getting really red; Arm getting really red; This case was reported by a nurse via call center representative and described the occurrence of pain in arm in a 89-year-old female patient who received Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent unspecified season) for prophylaxis.   On an unknown date, the patient received Influenza vaccine Quadrivalent unspecified season at an unknown dose. On an unknown date, unknown after receiving Influenza vaccine Quadrivalent unspecified season, the patient experienced pain in arm and erythema of extremities. On an unknown date, the outcome of the pain in arm and erythema of extremities were unknown.   It was unknown if the reporter considered the pain in arm and erythema of extremities to be related to Influenza vaccine Quadrivalent unspecified season.  Additional information received were as follows: The age at vaccination was not reported. The nurse reported that the patient received an unknown flu vaccine on unknown date and experienced her arm getting really red and sore. Due to this prior experience she would like to get a split dose of an unspecified flu vaccine. The healthcare professional did not know what past flu vaccine the patient received and they had not decided what flu vaccine she would get this season.
Suspected vaccination failure/new vaccine I got it, got on my face throat ear eye and was vaccinated; Got on my eye and was vaccinated; Got on my face throat ear and was vaccinated; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced vaccination failure (Verbatim: Suspected vaccination failure/new vaccine I got it, got on my face throat ear eye and was vaccinated) (serious criteria GSK medically significant), ophthalmic herpes zoster (Verbatim: Got on my eye and was vaccinated) (serious criteria GSK medically significant) and shingles (Verbatim: Got on my face throat ear and was vaccinated). The outcome of the vaccination failure was unknown and the outcome of the ophthalmic herpes zoster and shingles were not reported.   It was unknown if the reporter considered the vaccination failure, ophthalmic herpes zoster and shingles to be related to Shingles vaccine.     It was unknown if the company considered the vaccination failure, ophthalmic herpes zoster and shingles to be related to Shingles vaccine.   Additional Information: GSK receipt date: 2-Mar-2023 The case was received from the patient via interactive digital media. The patient stated that not fun.  The patient was vaccinated and got them on face, throat, ear, eye. When they came out with new vaccine got them in a hurry and said once that had them more prone to get them again.  The vaccine kept the patient from getting them so bad being treated soon was very important. This case was considered as suspected vaccination failure since the details regarding the completion of primary vaccination schedule, time to onset and laboratory confirmation of shingles were unknown at the time of reporting. The follow-up could not be possible as no contact details were available.
5 days after my vaccination I woke up in the middle of the night to pain in my arm pit of the arm the vaccine was administered. My lymph nodes in my groin, neck, clavicle, and arm pit are visibly inflamed. The left side of my face and neck are swollen as well. I am having tingling and numbness down my left arm and in my fingers. I am feeling very light headed and short of breath.
Patient reported itching all over body overnight. No rash/redness/warmth at injection site reported. No swelling or difficulty breathing. She has been taking oral diphenhydramine. Counseled to also take cimetidine to increase histamine blockage and to call her physician.
Loss of taste (my family thought a burrito was flavorful but it tasted like soggy tortilla to me. Masala and ginger tea tasted like hot water). Loss of taste persists two days after the vaccine. I also had weakness, body aches, and a fever a day after the vaccine; significant improvement two days after,
Child woke up from a nap while at baby sitter's with hive-like swellings that were very itchy approximately 4 hrs. after receiving MMR #2; Varivax #2; and Hep A #1. The babysitter called her mother who then called me asking what to do. I suggested giving BENADRYL and ascertained there was no difficulty breathing, swelling of lips or tongue, and no fever. The "hives" were on the child's extremities, trunk and face. She had no other symptoms.The babysitter gave her BENADRYL and applied calamine lotion to "hives". I called mom an hour later an found that the redness had subsided and the child was running & jumping around playing and in no distress. I instructed the mother to continue to observe the child for difficulty breathing and for increased swellling. If noted, the child should be taken to the emergency room or call 911. I spoke with the mother the next morning and all hives were clear and the child is fine. She had given her BENADRYL and the applied a corisine cream to the hives the night before.
Fever, chills, vomiting, nausea on day #3 of not being able to work.
Moving at slower pace; Fever; This spontaneous case was reported by a consumer and describes the occurrence of BRADYKINESIA (Moving at slower pace) and PYREXIA (Fever) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced BRADYKINESIA (Moving at slower pace) and PYREXIA (Fever). At the time of the report, BRADYKINESIA (Moving at slower pace) and PYREXIA (Fever) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided by the reporter. No treatment details were provided by the reporter.
Patient mentioned that she has been having a reaction that possibly is a side effect from her current medication therapy. Per Spanish translator, she's been getting numbness of the tongue and after she received the vaccine, around 10-13 minutes after, she informed me that she felt that the numbness on her tongue got worse. I asked if her tongue is swollen, her throat tightening and if she has a hard time breathing. She said no. There are no physical signs of anaphylaxis.  I gave her Benadryl and asked her to stay for 15 more minutes. I have been checking her in between her  additional 15mins observation and she says she feels better. She wanted to leave. She mentioned she's a little dizzy before she left.  I informed her that if she feels worse when she gets home, she needs to see a Doctor right away.
Hospitalized 3/24/22-4/13/22. Respiratory failure, obtunded>intubation, PNA, sepsis, altered mental status, CHF,  +FOB, pulmonary edema, O2, UTI.
pain; This is a spontaneous report from a contactable consumer or other non hcp received from a Pfizer sponsored program. A patient of unspecified age and gender received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot Number and Expiration date was not reported), dose 1 via an unspecified route of administration on 13May2021 as 1ST DOSE, SINGLE DOSE for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. It was reported that, the patient experienced pain on an unspecified date. It was reported that patient had their first dose on 13May2021 and scheduled to take the 2nd dose 10Jun2021. Reporter confirmed that patient had schedule today but would like to confirm if the date can be rescheduled due to Medical Appointment for his pain management. Reporter stated that patient did not experience any reactions after the first dose and pain right now. The outcome of the event was unknown.  Information on the lot/batch number has been requested.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021687630 same reporter/drug/event and different patient.
My shoulder is still sore; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team for a Pfizer sponsored program. The reporter is the patient.  A male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ARTHRALGIA (non-serious), outcome "not recovered", described as "My shoulder is still sore".  No follow-up attempts were possible; information about lot/batch number cannot be obtained. No further information was expected.
swollen face; skin turning red; This is a spontaneous report from a Pfizer-sponsored Program. A contactable consumer reported that a male patient of an unspecified age received BNT162B2 (Pfizer-BioNTech COVID-19 vaccine), via an unspecified route of administration on 27Feb2021 (lot number was not reported) as dose 1, single for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient experienced swollen face and the patient's skin was turning red after the first dose on 27Feb2021. The outcome of the events was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Mercury poisoning from routine childhood vaccinations. Thimerosal in my son's vaccines among other garbage caused him brain damage and other medical conditions. Stopped giving him toxic poisons in 1998 when I discovered the real truth. The follow up received on 1/14/03 states autism diagnosed at age 2 1/2, diarrhea, constipation. Annual follow up on 02/04/04: "Diagnosed Autistic September of 1998.  All vaccines damaged my son especially those with mercury.  Pt has not recovered from adverse events.  Vaccine induced Autism!
This spontaneous report was received from a pharmacist and refers to a female patient of unknown age. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant medications was provided. On 08-AUG-2018, the patient was inadvertently vaccinated intramuscularly with M-M-R II (recombinant human albumin) lot # N023150 with expiration date on 24-AUG-2019 (dose was not reported) for prophylaxis. The patient said that after administration (on the same day), the injection site stung. The patient did not seek medical attention and no treatment was given. She did not require hospitalization. The stinging went away and the patient recovered (on 08-AUG-2018). The causality assessment between the event and M-M-R II was not reported.
Pt vaccinated with DTP/OPV developed fever at 3PM to 102.3F, @ 5PM tremors began w/increased sleepiness. Problems continued through evening w/ pt. Seen in Urgent care next morning. Vitals stable & w/Tylenol problems resolved in next 24 hrs.
soreness in her arm; This is a spontaneous report from a contactable consumer (patient). A 63-years-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) on 18Mar2021 16:00 (Lot Number: EN6205, NDC number: 1000207028520) at SINGLE DOSE in Arm Left for covid-19 immunisation. Medical history included ongoing Rheumatoid arthritis, ongoing lupus , ongoing Osteoarthritis, ongoing autoimmune diseases.  The patient's concomitant medications were not reported. No Prior Vaccinations (within 4 weeks). The patient experienced soreness in her arm on 18Mar2021 with outcome of recovered on 19Mar2021.  It was probably less than 12 hours and the soreness was gone.   No follow-up attempts are needed. No further information is expected.
The day after my booster vaccine that I started to feel symptoms of sore muscles, joint pain, chills, weakness, fatigue. No fever. The day after I was starting to feel better, however I still had body aches, muscles pain and fatigue. As of now I am feeling good and back to normal with a little bit of fatigue.
Initial report was received 05 June 2008 from a health care professional. A 54-year-old male patient had received an intramuscular right deltoid injection of DECAVAC, lot number U2067DA, and an intramuscular right deltoid injections of MENACTRA, lot number U2632AA, and an intramuscular, left deltoid injection of PNEUMOVAX, lot number 0380U (Manufactured by Merck) on 03 June 2008 and one day later, he developed a 7cm by 6cm area of blotchy redness and edema with tenderness at the left deltoid region. The patient also complained of chills, muscle aches and pains, and generalized fatigue. Laboratory and diagnostic testing was marked "N/A" by the reporter. The patient had no pre-existing medical conditions and had not been ill at the time of vaccination. The patient had not been evaluated by their physician. At the time of the report, the patient's recovery status was not provided.
No additoinal adverse event; Pharmacist reports administration of MMR II via the intramuscular route instead of subcutaneously to a 16 year old patient on 07JUNE2022.; This spontaneous report was received from a pharmacist concerning a 16-year-old male patient. Information regarding the patient's current conditions, medical history and historical drug was not provided. His concomitant therapies included diphtheria vaccine toxoid, pertussis vaccine acellular, tetanus vaccine toxoid (TDAP), polio vaccine (POLIOVIRUS), hepatitis b vaccine (HEPATITIS-B), and varicella zoster vaccine rge (cho) (SHINGRIX).  On 07-JUN-2022, the patient was vaccinated with one dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) (dose, strength, lot, expiration date, and anatomical location were not provided) intramuscular route instead of subcutaneously (Incorrect route of product administration) for prophylaxis. The outcome of the event was reported as resolved.   The operator of vaccine was a trained healthcare professional (registered nurse). No additional information or adverse event were reported.
This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. On 21-DEC-2014 the patient was vaccinated with ZOSTAVAX 0.65ml, subcutaneous, lot # H012523, expiry date: 09-OCT-2013. On 21-DEC-2014 the patient received an expired dose of ZOSTAVAX. No adverse effect was reported. Additional information has been requested.
On 11 November 2008 we received a literature article. The authors conducted a case-cohort study estimating effectiveness of inactivated influenza vaccine in preventing inpatient/outpatient visits (emergency department [ED] and outpatient clinic). They compared vaccination status of laboratory-confirmed influenza cases with a cluster sample of children from a random sample of practices in 3 counties (subcohort) during the 2003-2004 and 2004-2005 seasons. The study was conducted in 3 counties. Children were defined as fully vaccinated if they received: (1) 2 vaccine doses in an influenza season, more than 24 days apart, with the second dose more than 14 days before ARI onset or (2) more than 1 vaccine dose in a prior influenza season and 1 dose in the current season more than 14 days before ARI onset. Children were partially vaccinated if they received (1) only 1 of 2 recommended doses during the current season more than 14 days before ARI onset or (2) 2 doses during the current season, with the second dose less than 24 days after the first or within 14 days of ARI onset. All other children were unvaccinated. During the 2003-2004 season a total of 8/210 children (who were fully vaccinated) and 21/210 children (who were partially vaccinated) experienced influenza infection. The authors identified 6 fully vaccinated children 6-23 months of age, and 13 partially vaccinated children 6-23 months of age, and 2 fully vaccinated children 24-59 months of age, and 8 partially vaccinated children 24-59 months of age. For the 2003-2004 season the company cannot exclude that the children received a Novartis influenza vaccine. During the 2004-2005 season the company had no product on the market. We received on 18 NOV 2008 and on 19 NOV 2008 from the author the information, that he has no further information. No change in assessment.
feeling sick; fever; Initial information received on 09-Dec-2021 regarding an unsolicited valid non-serious case received from a consumer/ non-Healthcare professional.  This case involves a 30-year-old male patient who experienced feeling sick and fever while receiving INFLUENZA VACCINE and Corona virus disease (COVID-19) VACCINE MODERNA and while treated with DUPILUMAB [DUPIXENT].  The patient past medical history, medical treatment, vaccination and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (batch number and expiry date: not reported) via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient received a second booster dose of suspect COVID-19 VACCINE MODERNA not produced by Sanofi Pasteur (batch number and expiry date: not reported) via unknown route in unknown administration site for prophylactic vaccination.  On 23-Mar-2018, the patient started taking DUPIXENT (DUPILUMAB) Solution for injection 300 mg subcutaneous (with an unknown batch number and expiry date) for Dermatitis atopic. In context of COVID19 crisis, lot number and expiry date was not requested.    On 03-Dec-2021, the patient developed a non-serious feeling sick (malaise) and fever (pyrexia) (unknown latency) following the administration of INFLUENZA VACCINE and COVID-19 VACCINE MODERNA.  On 03-DEC-2021 the patient developed a non-serious event feeling sick (malaise) and fever (pyrexia) 3 years 8 months 11 days following the first dose intake and (unknown latency) following the last dose intake of DUPILUMAB.  It was reported " Patient called stated he got Corona virus disease (COVID-19) Covid booster (Moderna) and Flu vaccine about one week ago and has been feeling sick and has fever ever since. Patient stated he has similar issues after second Corona virus disease (COVID-19) Covid vaccine".  DUPILUMAB (DUPIXENT) was continued.  It was not reported if the patient received a corrective treatment for the events.  At time of reporting, the outcome was reported as unknown.  There will be no information available on the batch number for this case.